

Population Mechanisms of Risk of Development of Cholelithiasis, Algorithms of Early Diagnosis, Prevention and Optimization of its Treatment Among the Population of the Fergana Valley of the Gerontological Group


Mamasaliev N. S.

Salakhidinov S. Z.

Mamasaliev Z. N.

Olimova N. A.

Andijan State Medical Institute, Uzbekistan

	<p>Abstract</p> <p>The article presents modern, foreign and domestic data on the problem of epidemiology, prevention and treatment of cholelithiasis (gallstone disease). The analysis of population studies and preventive programs for cholelithiasis in the population of the gerontological and geriatric group is carried out. The article discusses modern recommendations for the use of screening, various types of preventive studies, conservative and surgical methods of treatment of cholelithiasis.</p>
<p>Keywords: Cholelithiasis, epidemiology, prevention, pharmaco-epidemiology, risk factors, geriatric features of early detection and treatment of cholelithiasis.</p>	

Introduction

The aim of the study is to study the prevalence, pharmacoepidemiology of cholelithiasis and its main risk factors among the male and female unorganized population of the gerontological group of the Fergana Valley to enable scientifically based planning and optimization of early diagnosis, prevention and treatment of this disease.

Materials and Methods

The object of the study The sample included a contingent of 4,500 individuals from the gerontological age population, formed using random number tables based on the nominal electoral lists of men and women in three regions of the Fergana Valley; as well as 779 patients with cholelithiasis who were undergoing inpatient treatment in the regional multidisciplinary hospitals of Andijan, Namangan and Fergana (for VEN analysis).

Subject of the research There were results of general clinical and biochemical blood tests, a survey, physical, instrumental and pharmacoepidemiological monitoring; as well as the method of “daily nutrition reproduction” adapted to the peculiarities of Uzbek cuisine.

Research methods

To solve the set tasks, epidemiological, clinical, laboratory, biochemical, instrumental, pharmacoepidemiological and statistical research methods were used, as well as the “daily nutrition reproduction” method.

Results and Discussion

Primary and secondary prevention of chronic non-communicable diseases (CNCD), including cholelithiasis (ChT) is approved as the most effective means of reducing morbidity and mortality of people with non-communicable pathologies. First of all, this is associated with the implementation, in the example of other CNCD, of a population strategy and a high-risk strategy. Such a strategy is aimed at identifying the population with a high probability of developing CNCD/ChT.

The priority and mandatory step of primary prevention activities is the correction of risk factors based on data on population mechanisms of the risk of developing chronic renal disease with the implementation of regional algorithms for early diagnosis and treatment. To date, there are no scientific data obtained in this direction on cholelithiasis among the gerontologically aged population in the regions of Uzbekistan, in particular in the Fergana Valley. And scientific results on primary prevention and pharmacovigilance of cholelithiasis make it possible to achieve a further significant reduction in morbidity, disability and mortality from this disease, which is currently observed in developed countries.

Table – 1 Risk of developing cholelithiasis in the population of the gerontological group of the Fergana Valley in connection with risk factors

№	Risk factors	ChT, n	χ^2	P	RR	95% CI
1	Gender (men)	371	0,004	>0,05	0,997	0,914-1,088
2	Gender (women)	516	0,004	>0,05	1,002	0,942-1,066
3	60-74 years	487	16,49	<0,001	1,135	1,064-1,211
4	75-89 years	376	17,12	<0,001	0,824	0,754-0,900
5	90 years and older	24	0,003	>0,05	1,013	0,652-1,572
6	Dyslipidemia	598	13,01	<0,001	0,903	0,856-0,952
7	Arterial hypertension	611	0,045	>0,05	1,005	0,957-1,056
8	Alcohol consumption	140	1,716	>0,05	0,891	0,750-1,058
9	Low consumption of vegetables and fruits	230	10,14	<0,001	1,212	1,073-1,368
10	Diabetes mellitus	233	0,826	>0,05	1,058	0,936-1,195
11	Use of antihypertensive drugs	483	7,664	<0,01	0,905	0,845-0,969
12	Burdened heredity	242	5,964	<0,01	0,857	0,758-0,968
13	Overweight	661	22,43	<0,001	0,889	0,890-0,930
14	Obesity	616	24,10	<0,001	0,872	0,828-0,917
15	Liver cirrhosis	33	6,904	<0,01	0,588	0,394-0,876
16	Comorbidity	416	0,637	>0,05	1,032	0,955-1,115

Table – 2 Risk of developing cholelithiasis in the population of women of gerontological age in the Fergana Valley in connection with risk factors

№	Risk factors	ChT, n	χ^2	P	RR	95%CI
1	60-74 years	268	17,19	<0,001	1,192	1,090-1,304
2	75-89 years	235	19,95	<0,001	0,767	0,687-0,857
3	90 years and older	13	0,536	>0,05	1,244	0,692-2,237
4	Dyslipidemia	337	3,453	<0,05	0,932	0,868-1,001
5	Arterial hypertension	353	0,037	>0,05	1,006	0,943-1,074
6	Alcohol consumption	2	0,525	>0,05	1,715	0,391-7,523
7	Low consumption of vegetables and fruits	116	23,48	<0,001	1,491	1,257-1,770
8	Diabetes mellitus	140	0,027	>0,05	1,013	0,866-1,186
9	Use of antihypertensive drugs	275	5,242	<0,05	0,895	0,816-0,981
10	Burdened heredity	121	6,370	<0,01	0,791	0,661-0,946
11	Overweight	369	8,990	<0,01	0,902	0,847-0,961
12	Obesity	354	10,94	<0,001	0,885	0,827-0,947
13	Liver cirrhosis	18	2,960	>0,05	0,626	0,366-1,071
14	Comorbidity	231	1,643	>0,05	1,070	0,963-1,190

Taking into account the above-stated literary background, we studied the population mechanisms of the risk of developing cholelithiasis among the gerontologically aged population of the Fergana Valley. The results obtained in the population of the gerontological group of the Fergana Valley on the risk of developing cholelithiasis in connection with risk factors are presented in Table 1. As follows from Table 1, each range of risk factor values corresponds to a certain level of risk of developing cholelithiasis. The prognosis of the risk of cholelithiasis based on the assessment of risk factors differs significantly: gerontological groups of low risk of developing cholelithiasis, moderate risk, high risk and very high risk are distinguished.

A very high risk of developing cholelithiasis in the gerontological group population of the Fergana Valley is confirmed by the following risk factors: 1) age 60–74 years ($X^2 = 16.49$; $P < 0.001$; $RR = 1.135$; $95\% \text{ CI} = 1.064–1.211$); 2) old age 75–89 years ($X^2 = 17.12$; $P < 0.001$; $RR = 0.824$; $95\% \text{ CI} = 0.754–0.900$); 3) dyslipidemia ($X^2 = 13.01$; $P < 0.001$; $RR = 0.903$; $95\% \text{ CI} = 0.856–0.952$); 4) low consumption of vegetables and fruits ($X^2 = 1.14$; $P < 0.001$; $RR = 1.212$; $95\% \text{ CI} = 1.073 – 1.368$); 5) overweight ($X^2 = 22.43$; $P < 0.001$; $RR = 0.889$; $95\% \text{ CI} = 0.890 – 0.930$); 6) obesity ($X^2 = 24.10$; $P < 0.001$; $RR = 0.872$; $95\% \text{ CI} = 0.828 – 0.917$). A high risk of developing cholelithiasis in this group of the Fergana Valley population is associated with the use of antihypertensive drugs ($X^2 = 7.664$; $P < 0.001$; $RR = 0.905$; $95\% \text{ CI} = 0.845 – 0.696$), a burdened heredity ($X^2 = 5.964$; $P < 0.001$; $RR = 0.857$; $95\% \text{ CI} = 0.758 – 0.968$) and liver cirrhosis ($X^2 = 6.904$; $P < 0.001$; $RR = 0.588$; $95\% \text{ CI} = 0.394 – 0.876$).

In the group of moderate risk of developing cholelithiasis, in this group of examined gerontological age patients of the Fergana Valley, the population - patients - were not found. And the low risk of developing cholelithiasis is asserted in connection with other seven risk factors: 1) male gender ($X^2 = 0.004$; $P < 0.001$; $RR = 0.997$; $95\% \text{ CI} = 0.914 - 1.088$); 2) female gender ($X^2 = 0.004$; $P > 0.05$; $RR = 1.002$; $95\% \text{ CI} = 0.942 - 1.066$); 3) with age of 90 years and older ($X^2 = 0.003$; $P > 0.05$; $RR = 1.013$; $95\% \text{ CI} = 0.652 - 1.577$); 4) arterial hypertension

Table – 3 Risk of developing cholelithiasis in the population of gerontologically aged men in the Fergana Valley in connection with risk factors

No	Risk factors	ChT, n	χ^2	P	RR	95%CI
1	60-74 years	219	1,902	>0,05	1,066	0,971-1,170
2	75-89 years	141	1,251	>0,05	0,918	0,793-1,064
3	90 years and older	11	0,782	>0,05	0,739	0,377-1,447
4	Dyslipidemia	261	11,49	<0,001	0,865	0,800-0,935
5	Arterial hypertension	258	0,010	>0,05	1,004	0,931-1,082
6	Alcohol consumption	138	2,601	>0,05	0,881	0,758-1,025
7	Low consumption of vegetables and fruits	114	0,740	>0,05	0,926	0,780-1,101
8	Diabetes mellitus	93	1,464	>0,05	1,125	0,927-1,365
9	Use of antihypertensive drugs	208	2,495	>0,05	0,918	0,829-1,018
10	Burdened heredity	121	0,854	>0,05	0,924	0,784-1,090
11	Overweight	292	14,61	<0,001	0,872	0,819-0,928
12	Obesity	262	13,62	<0,001	0,853	0,790-0,922
13	Liver cirrhosis	15	4,106	<0,05	0,542	0,297-0,987
14	Comorbidity	185	0,075	>0,05	0,984	0,878-1,103

(X² = 0.045; P>0.05; RR = 1.005; 95% CI = 0.957 – 1.056); 5) alcohol consumption (X² = 1.716; P>0.05; RR = 0.891; 95% CI = 0.750 – 1.058); 6) diabetes mellitus (X² = 0.826; P>0.05; RR = 1.058; 95% CI = 0.936 – 1.195); 7) comorbidity (X² = 0.637; P>0.05; RR = 1.032; 95% CI = 0.955 – 1.115).

Table 2 also presents the results of the analysis of the study and assessment of the risk of developing cholelithiasis in the population of women of gerontological age in the Fergana Valley in connection with risk factors.

In women of gerontological age in the Fergana Valley, a very high risk of developing cholelithiasis was confirmed due to the following risk factors: 1) age 60-74 years (X² = 17.19; P<0.001; RR = 1.192; 95% CI = 1.090-1.304); 2) age 75-89 years (X² = 19.95; P<0.001; RR = 0.767; 95% CI = 0.687-0.857); 3) low consumption of vegetables and fruits (X² = 23.48; P<0.001; RR = 1.491; 95% CI = 1.257-1.770); 4) obesity (X² = 10.94; P<0.001; RR = 0.885; 95% CI = 0.827 – 0.947). A high risk of developing cholelithiasis is noted in connection with a burdened heredity (X² = 6.370; P<0.001; RR = 0.791; 95% CI = 0.661 – 0.946) and excess weight of calves (X² = 8.990; P<0.001; RR = 0.902; 95% CI = 0.847 – 0.961).

In connection with the following risk factors, such as dyslipidemia (X² = 3.453; P<0.05; RR = 0.932; 95% CI = 0.868 – 1.001) and the use of antihypertensive drugs (X² = 5.242; P<0.05; RR = 0.895; 95% CI = 0.816 – 0.981), a moderate risk of developing cholelithiasis is confirmed in the examined female population of the gerontological group.

Low risk of developing cholelithiasis was associated with the following risk factors: age 90 years and above (X² = 0.536; P>0.05; RR = 1.244; 95% CI = 0.692 – 2.237), arterial hypertension (X² = 0.037; P>0.05; RR = 1.006; 95% CI = 0.943 – 1.074), alcohol consumption (X² = 0.525; P>0.05; RR = 1.715; 95% CI = 0.391 – 7.523), diabetes mellitus (X² = 0.027; P>0.05; RR = 1.013; 95% CI = 0.866 – 1.186), liver cirrhosis (X² = 2.960; P>0.05; RR = 0.626; 95% CI = 0.366 – 1.071) and comorbidity (X² = 1.643; P>0.05; RR = 1.070; 95% CI = 0.963 – 1.190).

Further, a similar statistical analysis was carried out in the population of gerontologically aged men in the Fergana Valley (Table 3).

It was noted that in this population group the risk of developing cholelithiasis is associated with 14 risk factors and all those examined are included in the very high risk, moderate and low risk groups; the high risk group is not observed. Thus, a very high risk of developing gallstone disease is confirmed in connection with dyslipidemia ($X^2 = 11.49$; $P < 0.001$; $RR = 0.865$; 95% CI = 0.800 – 0.935), overweight ($X^2 = 14.61$; $P < 0.001$; $RR = 0.872$; 95% CI = 0.819 – 0.928) and obesity ($X^2 = 13.62$; $P < 0.001$; $RR = 0.853$; 95% CI = 0.790 – 0.922).

A moderate risk of developing cholelithiasis in men of gerontological age is predicted in connection with liver cirrhosis ($X^2 = 4.106$; $P < 0.05$; $RR = 0.542$; 95% CI = 0.297 – 0.987).

Low risk of developing cholelithiasis in this population is confirmed by the following risk factors:

1) age 60–74 years ($X^2 = 1.902$; $P > 0.05$; $RR = 1.066$; 95% CI = 0.971–1.170); 2) age 75–89 years ($X^2 = 1.251$; $P > 0.05$; $RR = 0.918$; 95% CI = 0.793–1.064); 3) age ≥ 90 years ($X^2 = 0.782$; $P > 0.05$; $RR = 0.739$; 95% CI = 0.377–1.447); 4) arterial hypertension ($X^2 = 0.010$; $P > 0.05$; $RR = 1.004$; 95% CI = 0.931 – 1.082); 5) with alcohol consumption ($X^2 = 2.601$; $P > 0.05$; $RR = 0.881$; 95% CI = 0.758 – 1.025); 6) with low consumption of vegetables and fruits ($X^2 = 0.740$; $P > 0.05$; $RR = 0.926$; 95% CI = 0.780 – 1.101); 7) diabetes mellitus ($X^2 = 1.464$; $P > 0.05$; $RR = 1.125$; 95% CI = 0.927 – 1.365); 8) with the use of antihypertensive agents ($X^2 = 2.495$; $P > 0.05$; $RR = 0.918$; 95% CI = 0.829 – 1.018); 9) burdened heredity ($X^2 = 0.845$; $P > 0.05$; $RR = 0.924$; 95% CI = 0.784 – 8.090); 10) comorbidity ($X^2 = 0.075$; $P > 0.05$; $RR = 0.984$; 95% CI = 0.878 – 1.103).

Thus, the obtained new epidemiological data, in contrast to the previous and outdated clinical and statistical data of the literature, can significantly change the understanding of the risk of cholelithiasis in gerontological individuals of the Fergana Valley. Prognostic assessment of cholelithiasis in connection with its risk factors allows: 1) to identify individuals who have a very high risk of cholelithiasis and its complications; 2) to identify the gerontological population in groups of high, moderate and low risk of cholelithiasis. The use of such "rescreening" + "reclassification" can lead to increased efficiency: a) before nosological diagnosis of cholelithiasis, b) before nosological prevention of cholelithiasis and its complications, c) pharmacoprophylaxis and pharmacovigilance of cholelithiasis, d) preventive surgery of cholelithiasis; d) existing algorithms for examination, early diagnosis and optimization of treatment (surgical and conservative) of cholelithiasis among the population of the regions of Uzbekistan (in the example of the Fergana Valley) of the gerontological group.

Conclusion

In the formation of "aggressive" epidemiological conditions in relation to cholelithiasis among the gerontologically aged population of the Fergana Valley, exogenous and endogenous common factors play a key role. They are characterized by the following prevalence rates in men and women (≥ 60 –90 years), respectively: arterial hypertension - 42.1% and 57.9%, alcohol consumption - 98.4% and 1.6%, low consumption of vegetables and fruits - 39.8% and 60.2%, type 2 diabetes mellitus - 41.9% and 58.1%, overweight - 42.5% and 57.5%, obesity - 41.7% and 58.3%, burdened heredity - 52.8% and 47.2%, cirrhosis of the liver - 42.9% and 57.1%.

References

1. Абасов Ш.Ю., Алиев Р.К., Алиев А.К., Рамащенко П.Н. Предикторы “трудной” лапароскопической холецистэктомии в прогнозировании и профилактики повреждений желчных протоков. Известия Российской военно – медицинской академии. 2022; 41 (52): 14 – 15.
2. Алиев Р.К., Рамащенко П.Н., Майстренко М.А., Прядко А.С., Алиев А.К. Непреднамеренные травмы желчевыводящих протоков: пути профилактики и лечения Вестник Российской Военно – медицинской академии. 2021: 23 (3): 55 – 58.
3. Бебуришвили А.Г., Панин С.Н., Зюбина Е.Н., Нестеров С.С., Пузикова А.В. Холецистостомия при острой холецистите//Хирургия. Журнал имени Н.И. Пирогова. – 2020; №6 – С. – 45.
4. Ботыров Д.А. Геронтологические особенности холецистита в условиях Ферганской долины//Хирургия. 2024.
5. Бурдюков М.С., Нечипай А.М. Холедохолитиаз: обзор литературы. Доказательная гастроэнтерология. 2020; 9 (4): 55 – 64.
6. Балалыкин А.С. Эндоскопическая папиллосфинктеропия. Руководства по химической эндоскопии М. 1985; 290 – 314.
7. Лыткин М.И., Тетдаев А.М., Стойко Ю.М. Нужно ли защищать холецистостомию при остром холецистите?//Хирургия. – 1978; 7: 10 – 12.
8. Майстренко Н.А., Рамащенко П.Н., Прядко А.С., Алиев А.К. Обоснование хирургической тактики при ятрогенных повреждениях желчевыводящих протоков. Вестник хирургии им И.И. Грекова 2015: 174 (5): 22 – 30.
9. Майстренко Н.А., Ромащенко П.Н., Алиев А.К., Сибиров С.А. Острое повреждение желчевыводящих протоков. Вестник Российской Военно – Медицинской академии. 2016: 1 (53): 124 – 128.
10. Нургазинова А.К. Происхождение, развитие и современная трактовка понятий “коморбидность и колиморбидность”//Казанский Медицинский журнал. 2014; 2: 95: 292 – 294.
11. Прядко А.С., Ромащенко П.Н., Майстренко М.А., Алиев А.К. и др. Реализация программы “безопасная холецистэктомия” в Ленинградской области//Хирургия. Журнал имени Н.И. Пирогова. – 2023. - №10. – С. 109 – 116.
12. Ромащенко П.Н., Майстренко Н.А., Прядко А.С., Алиев А.К. Травмы желчевыводящих протоков и системный подход к их устранению//Анналы хирургической гепатологии. 2019; 24 (1): 71 – 80.
13. Ромащенко П.Н., Майсаренко Н.А., Прядко А.С., Алиев А.К., Алиев Р.К., Жеребцов Е.С. Профилактика и лечение повреждений желчевыводящих протоков у больных острым холециститом.//Анналы хирургической гепатологии. 2020: 25 (3): 20 – 31.
14. Цеймах А.Е., Куртуков В.А., Мищенко А.Н., Теплухин В.Н., Шойхет Я.Н. и др. Применение мини – инвазивных технологий литотрипсии и антеградной гидравлической литоэкстракции в комплексном лечении больных холедохолитиазам.//Хирургия. Журнал Имени Н.И. Пирогова. – 2023 - №4: С. 5 – 11.
15. ASGE Standards of Practice Committee, Buxbaum JL, Abbas Fehmi SM, Siltan S, Fishman DS, Qumseya BJ, Cortessis VK, Schilperoot H, Kysh L, Matsuoka L, Yachimski P, Agrawal

- D, Gurudu SR, Jamil LH, Jue TL, Khashab MA, Law JK, Lee SK, Naveed M, Sauhney MS, Thosani N, Yang J, Wani SB, ASGE guideline on the role of endoscopy in the evaluation and management of choledocholithiasis. *Gastrointest Endosc.* 2019; 89 (6): 1075 – 1105. E 15. <https://doi.org/10.1016/j.gie.2018.10.001>.
16. Barbara L, Sama C, Morselli Labate AM, Taroni F, Rusticali AG, Festi D, Sapio C, Roda E, Banterle C, Puci A. A population study on the prevalence of gallstone disease: the Sirmione Study. *Hepatology.* 1987; 7(5):913-916. <https://doi.org/10.1002/hep.1840070520>.
 17. Bignell M, Dearing M, Hindmarsh A, Rhodes M. ERCP and endoscopic sphincterotomy (ES): a safe and definitive management of gallstone pancreatitis with the gallbladder left in situ. *Journal of Gastrointestinal Surgery.* 2011; 15(12): 2205 – 2210. <https://doi.org/10.1007/S11605-011-1729-X>
 18. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones. *J Hepatol.* 2016;65(1):146 – 180. <https://doi.org/10.1016/j.jhep.2016.03.005>.
 19. Felekouras E, Petrou A, Neofytou K, Moris D, Dimitrokallis N, Bramis K, Griniatsos J, Pikoulis E, Diamantis T. Early or Delayed Intervention of Bile Duct Injuries following Laparoscopic Cholecystectomy? A Dilemma Looking for an Answer. *Gastroenterology Research and Practice.* 2015;2015:104235. <https://doi.org/10.1155/2015/104235>.
 20. Hariharan D, Psaltis E, Schole Field JH, Lobo DN, Quality of life and Medico – Legal Implications Following Iatrogenic Bile Duct Injuries. *World Journal of Surgery* 2017;41 (1):98. <https://doi.org/10.1007/S00268-016-3677-9>.
 21. Lukina Yu V, Kutishenko NP, Martsevich SYu. The problem of adherence to the treatment in modern medicine: possibilities of solution, impact on the effectiveness of therapy and disease outcomes. *Rational Pharmacotherapy in Cardiology.* 2017;13 (4): 519 – 24.
 22. L Yu J, Lin Q, Fang Z, et al. Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease. *Front Endocrinol (Lausanne).* 2022;13:1032557. doi:10.3389/fenr.2022.1032557.
 23. Lee HM, Min SK, Lee MK. Long – term results of laparoscopic common bile duct exploration by cholecystectomy for choledocholithiasis: 15 – year experience from a single center – *Ann Surg Treat Res.* 2014;86:1 – 4. <https://doi.org/10.4174/astr.2014.86.1.1>.
 24. Maystrenko N, Romashenko P, Aliev A, Sibirev SA. Acute injury of bile ducts. *Research Journal of Medical Sciences.* 2016; 10(1): 740 – 742.
 25. Manes G, Paspatis G, Aabakken L, Anderloni A, Arvanitakis M, Ah Soune P, Barthet M, Domogk D, Dumonceau JM, Gigot JK, Hritz I, Karamanolis G, Laghi A, Mariani A, Paraskeva K, Pohl J, Ponchon I, Swahn F, Ter Stige RWF, Tingali A, Verakis A, Williams EJ, van Hooft JE. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy.*2019;51(5): 472 – 490. <https://doi.org/10.1055/a-0862-0346>.
 26. Mc. Nicoll CF, Pastorino A, Farooq U, ST Hill CR. Choledocholithiasis. In: *Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing.* 2022.PMID:28722990.
 27. Masci E, Toti G, Mariani A, Curioni S, Lomarzi A, Dinelli M, Minoli G, Crosa C, Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. Complications of diagnostic and therapeutic

- ERCP: a prospective multi center Study American Journal of Gastroenterology. 2001:96 (2): 417 – 423. <https://doi.org/10.1111/j.1572-0241-2001-03594-x>.
28. Sahajpal AK, Chow SC, Dixon E, Greig PD, Gallinger S, Wei AC. Bile duct injuries associated with laparoscopic cholecystectomy: timing of repair and long – term outcomes. The Archives of Surgery. 2010:145 (8): 757 – 760. <https://doi.org/10.1001/arch surg.2010.153>.
29. Strasberg SM, Brunt LM. Rationale and use of the critical view of safety in laparoscopic cholecystectomy. Journal of the American College of Surgeons. 2010:211 (1):132 – 137. <https://doi.org/10.1016/j.jam collsurg.2010.02.053>.
30. Schirmer BD, Winters KL, Edlich RF. Cholelithiasis and cholecystitis. J long Trem Eff Med Implants. 2005: 15 (3): 329 – 334. <https://doi.org/10.1615/j longtremeffmedimplants. V 15:3 - 90>.
31. Shojaiefard A, Esmaeilzadeh M, Ghafouri A, Mehrabi A, Various techniques for the surgical treatment of common bile duct stones: a meta review. Gastroenterology Research and Practice. 2009:2009:840208. <https://doi.org/10.1155/2009/840208>.
32. Salminen P, Laine S, Gullichsen R. Severe and fatal complications after ERCP: analysis of 2555 procedures in a single experienced center. Surgical Endoscopy. 2008:22(9): 1965 – 1970. <https://doi.org/10.1007/S00464 - 007 - 9711 - 0>.
33. Siiki A, Tamminen A, Kuusanmaki P, ERCP procedures in a Finish community hospital: a retrospective analysis of 1207 cases. Scandinavian Journal of Surgery. 2012:101(1):45 – 50. <https://doi.org/10.117/145749691210 100109>.
34. Wang L, Yu WF. Obstructive jaundice and perioperative management. Acta Anaes the siologica Taiwanica. 2014:52(1):22 – 25. <https://doi.org/10.1016/j.aat.2014.03.002>.